Skip to content

Matthias E. Liechti

University Hospital of Basel, University of Basel

176 papers in the library · 10,050 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

Monoamine Receptor and Transporter Interaction Profiles of 4‐Alkyl‐Substituted 2,5‐Dimethoxyamphetamines

The FASEB Journal May 1, 2022 Dino Luethi, Deborah Rudin, Marius C. Hoener et al.

Background Various ring‐substituted phenethylamines and amphetamines are used recreationally due to their mind‐altering effects. Furthermore, such psychedelic substances have recently gained increased interest as prospective therapeutics. Here, we studied the pharmacological properties of 4‐alkylated 2,5‐dimethoxyamphetamines in vitro. Specifically, we assessed the effect of the 4‐alkyl chain...

DOI: 10.1096/fasebj.2022.36.s1.r2691 (opens in new tab) Serotonin Monoamine neurotransmitter Alkyl Transporter +5

Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging April 29, 2022 Mihai Avram, Felix Müller, Helena Rogg et al. 43 citations

Psychedelics, empathogens, and psychostimulants evoke thalamocortical hyperconnectivity with sensorimotor areas, akin to findings in patients with psychotic disorders.

DOI: 10.1016/j.bpsc.2022.04.003 (opens in new tab) MDMA Amphetamine Hallucinogen Pharmacology

Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: ,α-DEPEA and DPIA

European Neuropsychopharmacology April 1, 2022 Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel et al. 7 citations

3,4-methylenedioxyamphetamine (MDA) is a psychoactive compound chemically related to the entactogen MDMA. MDA shares some of the entactogenic effects of MDMA but also exerts stimulant effects and psychedelic properties at higher doses. Here, we examined the pharmacological properties of MDA analogs and related amphetamine-based compounds detected in street drug samples or in sport supplements....

DOI: 10.1016/j.euroneuro.2022.03.006 (opens in new tab) MDMA Serotonin Pharmacology Monoamine neurotransmitter +5

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Neuropsychopharmacology February 25, 2022 Friederike Holze, Laura Ley, Felix Müller et al. 223 citations

Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women,...

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

Frontiers in Pharmacology February 9, 2022 Karolina E. Kolaczynska, Dino Luethi, Dino Luethi et al. 16 citations

3,4,5-Trimethoxyphenethylamine (mescaline) is a psychedelic alkaloid found in peyote cactus. Related 4-alkoxy-3,5-dimethoxy-substituted phenethylamines (scalines) and amphetamines (3C-scalines) are reported to induce similarly potent psychedelic effects and are therefore potential novel therapeutics for psychedelic-assisted therapy. Herein, several pharmacologically uninvestigated scalines and...

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants

Psychopharmacology January 25, 2022 Felix Müller, Elias Kraus, Friederike Holze et al. 64 citations

Abstract Background LSD and psilocybin are increasingly used in phase I trials and evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring drug-like experiences after the acute substance effects have worn off was described for both substances and especially attributed to LSD. According to the DSM-V, the persisting and distressing manifestation of these experiences is...

Dosing Psychedelics and MDMA.

Current Topics in Behavioral Neurosciences 2022 Matthias E. Liechti, Friederike Holze 35 citations

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others....

DOI: 10.1007/7854_2021_270 (opens in new tab) Full text (opens in new tab) Microdosing Ego-dissolution dose Good effect dose Personalized medicine +1

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects

Clinical Pharmacology & Therapeutics November 7, 2021 Anna M Becker, Friederike Holze, Tanja Grandinetti et al. 177 citations

The psychedelic psilocybin is being investigated for the treatment of depression and anxiety. Unclear is whether antidepressant treatments interact with psilocybin. The present study used a double‐blind, placebo‐controlled, crossover design with two experimental test sessions to investigate the response to psilocybin (25 mg) in healthy subjects after pretreatment with escitalopram or placebo....

DOI: 10.1002/cpt.2487 (opens in new tab) Psilocybin Escitalopram Placebo Crossover study +5

Safety pharmacology of acute LSD administration in healthy subjects

Psychopharmacology September 13, 2021 Friederike Holze, Toya V Caluori, Patrick Vizeli et al. 57 citations

Abstract Rationale Lysergic acid diethylamide (LSD) is used in psychiatric and psychological research and investigated as a potential treatment for medical and psychiatric disorders, including depression, anxiety, and cluster headache. Objectives Safety data on clinical safety are available from small studies but not from larger samples. We report safety pharmacology data from a large pooled...

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

International Journal of Molecular Sciences July 31, 2021 Karolina E. Kolaczynska, Jan Thomann, Marius C. Hoener et al. 35 citations

Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using...

DOI: 10.3390/ijms22158277 (opens in new tab) Cathinone Pharmacology Potency Dopamine transporter +4

Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin

Frontiers in Pharmacology July 13, 2021 Friederike Holze, Isidora Avedisian, Nimmy Varghese et al. 66 citations

The psychedelic lysergic acid diethylamide (LSD) has experienced a revival in research, including clinical trials that evaluate LSD-assisted psychotherapy. LSD induces perceptual alterations and influences emotion processing in ways that may support psychotherapy. Here, we investigated the effects of LSD on emotional empathy and mediating role of the serotonin 5-hydroxytryptamine-2A (5-HT 2A )...

Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics

Experimental Neurology June 4, 2021 Deborah Rudin, Matthias E. Liechti, Dino Luethi 48 citations

New psychoactive stimulants and psychedelics continue to play an important role on the illicit new psychoactive substance (NPS) market. Designer stimulants and psychedelics both affect monoaminergic systems, although by different mechanisms. Stimulant NPS primarily interact with monoamine transporters, either as inhibitors or as substrates. Psychedelic NPS most potently interact with...

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.

Scientific Reports May 25, 2021 Patrick Vizeli, Isabelle Straumann, Friederike Holze et al. 54 citations

Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no pharmacogenetic studies on LSD. In vitro metabolic studies indicate that several cytochrome P450 (CYP) isoforms (e.g., CYP2D6, CYP1A2, and CYP2C9) are involved in LSD metabolism, but in vivo data are scarce. The present study examined the...

Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies

Journal of Psychopharmacology March 30, 2021 Erich Studerus, Patrick Vizeli, Samuel Harder et al. 51 citations

Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is used both recreationally and therapeutically. Little is known about the factors influencing inter- and intra-individual differences in the acute response to MDMA. Effects of other psychoactive substances have been shown to be critically influenced by personality traits and mood state before intake. Methods: We pooled data from...

Drugs of Abuse Affecting 5-HT_2B Receptors

5-HT2B Receptors 2021 Dino Luethi, Matthias E. Liechti 3 citations

Stimulant and psychedelic drugs of abuse exert their effects through interactions with monoaminergic systems. Compared to other monoaminergic receptors and transporters, the 5-hydroxytryptamine 2B (5-HT_2B) receptor represents a relatively little studied target of serotonergic drugs of abuse. However, studies suggest the involvement of 5-HT_2B receptors in the mechanism of action of...

MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens

Neuropsychopharmacology November 20, 2020 Felix Müller, Friederike Holze, Patrick C. Dolder et al. 43 citations

Abstract It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of hallucinogens and it was speculated that these shifts in connectivity underlie the characteristic subjective drug effects. In this study, we...

Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects

Frontiers in Psychiatry October 22, 2020 Felix Müller, Markus Mühlhauser, Friederike Holze et al. 31 citations

A 39-year-old female patient suffering from severe, treatment-resistant depression and other symptoms associated with a complex personality disorder was admitted to our open psychiatric ward for an experimental treatment with lysergic acid diethylamide (LSD). The substance was administered in repeated weekly and ascending doses. Curiously, there were no substantial acute subjective effects of...

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

European Neuropsychopharmacology October 17, 2020 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 121 citations

There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to...

DOI: 10.1016/j.euroneuro.2020.10.002 (opens in new tab) Anxiety Mood Vigilance psychology Cognition +7

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Neuropsychopharmacology October 15, 2020 Friederike Holze, Patrick Vizeli, Laura Ley et al. 243 citations

Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25...

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Journal of Psychopharmacology October 8, 2020 Yasmin Schmid, Peter Gasser, Peter Oehen et al. 82 citations

Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants

Clinical Pharmacology & Therapeutics September 25, 2020 Friederike Holze, Matthias E. Liechti, Nadia R. P. W. Hutten et al. 63 citations

“Microdoses” of lysergic acid diethylamide (LSD) are used recreationally to enhance mood and cognition. Increasing interest has also been seen in developing LSD into a medication. Therefore, we performed a pharmacokinetic‐pharmacodynamic study using very low doses of LSD. Single doses of LSD base (5, 10, and 20 µg) and placebo were administered in a double‐blind, randomized, placebo‐controlled...

DOI: 10.1002/cpt.2057 (opens in new tab) Lysergic acid diethylamide Pharmacodynamics Pharmacokinetics Pharmacology

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

ACS Pharmacology & Translational Science August 31, 2020 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 134 citations

Despite preclinical evidence for psychedelic-induced neuroplasticity, confirmation in humans is grossly lacking. Given the increased interest in using low doses of psychedelics for psychiatric indications and the importance of neuroplasticity in the therapeutic response, this placebo-controlled within-subject study investigated the effect of single low doses of LSD (5, 10, and 20 μg) on...

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology August 25, 2020 Johannes G. Ramaekers, Nadia R. P. W. Hutten, Natasha L. Mason et al. 95 citations

Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim: The present...

Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans

Metabolites July 27, 2020 Andrea E. Steuer, Daria Kaelin, Martina I. Boxler et al. 32 citations

Psychoactive stimulants are a popular drug class which are used recreationally. Over the last decade, large numbers of new psychoactive substances (NPS) have entered the drug market and these pose a worldwide problem to human health. Metabolomics approaches are useful tools for simultaneous detection of endogenous metabolites affected by drug use. They allow identification of pathways or...

Para-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells

International Journal of Molecular Sciences April 18, 2020 Xun Zhou, Jamal Bouitbir, Matthias E. Liechti et al. 29 citations

Halogenation of amphetamines and methcathinones has become a common method to obtain novel psychoactive substances (NPS) also called “legal highs”. The para-halogenated derivatives of amphetamine and methcathinone are available over the internet and have entered the illicit drug market but studies on their potential neurotoxic effects are rare. The primary aim of this study was to explore the...

DOI: 10.3390/ijms21082841 (opens in new tab) Sh-sy5y Amphetamine Pharmacology Neurotoxicity +11